Ablukast: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
{{Short description|A leukotriene receptor antagonist used in the treatment of asthma and allergic rhinitis}}
{{DISPLAYTITLE:Ablukast}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (E)-1-((1-(4-(4-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)butoxy)phenyl)propyl)sulfonyl)azetidine-3-carboxylic acid
| image = Ablukast.svg
| width = 200
| tradename = Ablukast
| legal_status = Rx-only
| routes_of_administration = Oral
| bioavailability = 64%
| protein_bound = 99%
| metabolism = Hepatic
| elimination_half-life = 2.7–5.5 hours
| excretion = Fecal (86%), renal (10%)
}}


'''Ablukast''' is a [[leukotriene receptor antagonist]] (LTRA) used primarily in the management of [[asthma]] and [[allergic rhinitis]]. It functions by blocking the action of leukotrienes, which are chemicals in the body that react to allergens and cause inflammation, bronchoconstriction, and mucus production.
== Overview ==
'''Ablukast''' is a [[leukotriene receptor antagonist]] used in the management of [[asthma]] and [[allergic rhinitis]]. It functions by blocking the action of leukotrienes, which are inflammatory chemicals the body releases after coming in contact with an allergen or irritant. By inhibiting these chemicals, Ablukast helps to reduce inflammation, bronchoconstriction, and mucus production in the airways.


==Mechanism of Action==
== Mechanism of Action ==
Ablukast works by selectively inhibiting the cysteinyl leukotriene receptor type 1 (CysLT1) in the lungs and bronchial tubes. This inhibition prevents leukotrienes from binding to their receptors, thereby reducing inflammation, bronchoconstriction, and mucus secretion associated with asthma and allergic rhinitis.
[[File:Ablukast.svg|thumb|right|Chemical structure of Ablukast]]
Ablukast works by selectively binding to [[cysteinyl leukotriene receptor]]s (CysLT1) in the respiratory tract. Leukotrienes are derived from [[arachidonic acid]] and are potent mediators of inflammation. By blocking these receptors, Ablukast prevents leukotrienes from exerting their effects, which include bronchoconstriction, increased vascular permeability, and recruitment of inflammatory cells.


==Pharmacokinetics==
== Clinical Uses ==
Ablukast is administered orally and has a bioavailability of approximately 64%. It is highly protein-bound (99%) and undergoes extensive hepatic metabolism. The elimination half-life of Ablukast ranges from 2.7 to 5.5 hours, and it is primarily excreted in the feces (86%) with a small amount excreted renally (10%).
Ablukast is primarily used in the treatment of chronic asthma. It is not intended for the relief of acute asthma attacks but is used as a maintenance therapy to prevent symptoms. Additionally, Ablukast is effective in treating symptoms of [[allergic rhinitis]], such as nasal congestion, sneezing, and runny nose.


==Clinical Use==
== Administration and Dosage ==
Ablukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children. It is also used to relieve symptoms of allergic rhinitis, such as sneezing, runny nose, and nasal congestion. Ablukast is not indicated for the relief of acute asthma attacks.
Ablukast is administered orally, typically in the form of tablets. The dosage may vary depending on the age of the patient and the severity of the condition being treated. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration.


==Side Effects==
== Side Effects ==
Common side effects of Ablukast include headache, dizziness, abdominal pain, and fatigue. Rare but serious side effects may include liver dysfunction and neuropsychiatric events such as agitation, aggression, and hallucinations.
Common side effects of Ablukast include headache, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. In rare cases, patients may experience mood changes or allergic reactions. It is important for patients to report any unusual symptoms to their healthcare provider.


==Contraindications==
== Contraindications and Precautions ==
Ablukast is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised in patients with hepatic impairment.
Ablukast should be used with caution in patients with a history of liver disease, as it is metabolized by the liver. It is contraindicated in patients with known hypersensitivity to the drug or any of its components. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions.


==Related Pages==
== Related Pages ==
* [[Asthma]]
* [[Asthma]]
* [[Allergic rhinitis]]
* [[Allergic rhinitis]]
* [[Leukotriene receptor antagonist]]
* [[Leukotriene receptor antagonist]]
* [[Bronchoconstriction]]
* [[Cysteinyl leukotriene receptor]]


==Gallery==
<gallery>
File:Ablukast.svg|Chemical structure of Ablukast
</gallery>
[[Category:Leukotriene receptor antagonists]]
[[Category:Asthma]]
[[Category:Respiratory system drugs]]
[[Category:Respiratory system drugs]]
[[Category:Anti-inflammatory agents]]

Latest revision as of 03:44, 13 February 2025


Overview[edit]

Ablukast is a leukotriene receptor antagonist used in the management of asthma and allergic rhinitis. It functions by blocking the action of leukotrienes, which are inflammatory chemicals the body releases after coming in contact with an allergen or irritant. By inhibiting these chemicals, Ablukast helps to reduce inflammation, bronchoconstriction, and mucus production in the airways.

Mechanism of Action[edit]

Chemical structure of Ablukast

Ablukast works by selectively binding to cysteinyl leukotriene receptors (CysLT1) in the respiratory tract. Leukotrienes are derived from arachidonic acid and are potent mediators of inflammation. By blocking these receptors, Ablukast prevents leukotrienes from exerting their effects, which include bronchoconstriction, increased vascular permeability, and recruitment of inflammatory cells.

Clinical Uses[edit]

Ablukast is primarily used in the treatment of chronic asthma. It is not intended for the relief of acute asthma attacks but is used as a maintenance therapy to prevent symptoms. Additionally, Ablukast is effective in treating symptoms of allergic rhinitis, such as nasal congestion, sneezing, and runny nose.

Administration and Dosage[edit]

Ablukast is administered orally, typically in the form of tablets. The dosage may vary depending on the age of the patient and the severity of the condition being treated. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration.

Side Effects[edit]

Common side effects of Ablukast include headache, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. In rare cases, patients may experience mood changes or allergic reactions. It is important for patients to report any unusual symptoms to their healthcare provider.

Contraindications and Precautions[edit]

Ablukast should be used with caution in patients with a history of liver disease, as it is metabolized by the liver. It is contraindicated in patients with known hypersensitivity to the drug or any of its components. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions.

Related Pages[edit]